1. Epigenetic Changes in Prostate Cancer: Implication for Diagnosis and Treatment
   Long-Cheng Li et al, 2005, JNCI: Journal of the National Cancer Institute CrossRef
2. Suberoylanilide hydroxamic acid (vorinostat) represses androgen receptor expression and acts synergistically with an androgen receptor antagonist to inhibit prostate cancer cell proliferation
   Deborah L. Marrocco et al, 2007, Molecular Cancer Therapeutics CrossRef
3. Chronic Administration of Valproic Acid Inhibits Prostate Cancer Cell Growth In vitro and In vivo
   Qinghua Xia et al, 2006, Cancer Research CrossRef
4. Valproic acid induces growth arrest, apoptosis, and senescence in medulloblastomas by increasing histone hyperacetylation and regulating expression of p21Cip1, CDK4, and CMYC
   Xiao-Nan Li et al, 2005, Molecular Cancer Therapeutics CrossRef
5. Mechanisms of Cell Death Induced by Histone Deacetylase Inhibitors in Androgen Receptor–Positive Prostate Cancer Cells
   Oskar W. Rokhlin et al, 2006, Molecular Cancer Research CrossRef
6. Sulforaphane inhibits histone deacetylase activity in BPH-1, LnCaP and PC-3 prostate epithelial cells
   Melinda C. Myzak et al, 2006, Carcinogenesis CrossRef
7. From HDAC to Voltage-Gated Ion Channels: What’s Next? The Long Road of Antiepileptic Drugs Repositioning in Cancer
   Michele Pellegrino et al, 2022, Cancers CrossRef
8. The relevance of estrogen receptor-β expression to the antiproliferative effects observed with histone deacetylase inhibitors and phytoestrogens in prostate cancer treatment
   Mark Stettner et al, 2007, Molecular Cancer Therapeutics CrossRef